- Home
- Blog Details
Three international health organizations are working together on a project to investigate the viability of preserving experimental vaccines for unusual infectious diseases , according to a senior official from the vaccine alliance Gavi. The idea is to have these vaccinations on hand for testing during outbreaks so that a quicker reaction may be made. The Global Virtual Pooled Inventory (GVPI), an initiative of the World Health Organization (WHO), the Coalition for Epidemic Preparedness Innovations (CEPI), and Gavi, will be maintained by these organizations.
The GVPI's initial focus will be on Marburg and the Sudanese strain of Ebola, two devastating viral hemorrhagic fevers. There are currently no viable treatments or vaccines for these illnesses. Both illnesses saw breakouts in Africa the previous year, which underscored the urgent need for a proactive strategy to combat them.
According to the WHO, the Ebola outbreak in Uganda resulted in 142 confirmed cases and 55 fatalities. There were 25 Marburg cases in Tanzania and Equatorial Guinea, all of which resulted in verified fatalities. Equatorial Guinea also reported 23 other suspected cases, all of which ended in death. Public health measures were put in place in response to these outbreaks, such as patient testing and isolation, which successfully stopped the spread of the diseases. New vaccines could not, however, be tested in humans due to the urgency of the situation.
Although the quick action saved lives, it also demonstrated the necessity for reliable vaccines to be accessible during subsequent outbreaks. Even while the response was prompt, Aurelia Nguyen, the chief program strategy officer at Gavi, stated that the availability of vaccines to effectively stop future outbreaks was still a long way off.
The GVPI's precise specifications are still being developed. Nguyen said that in order for the program to be successful, agreements with vaccine producers may need to be made in advance. Once an outbreak occurs, these agreements would guarantee the prompt delivery of a predetermined number of vaccine doses. The Zaire strain of Ebola has previously been successfully treated using a similar approach.
The creation of Marburg and Ebola Sudan vaccines is now being carried out by numerous organizations and academic institutions. These organizations include Oxford University, Merck, the Sabin Institute, the International Aids Vaccine Institute (IAVI), and the Serum Institute of India. These organizations are making steady progress in this area of research.
Vaccines would need to pass safety and immune response tests in humans, often through phase II trials, in order to be added to the GVPI. This stipulation guarantees that the vaccines adhere to the requirements for stockpile inclusion.
If the GVPI is successful, it might be used as a template for treating other fatal diseases and improving pandemic preparedness. Due to a number of variables, including climate change, the threat posed by such diseases is rising. In order to strengthen global health security and lessen the effects of epidemics globally, the WHO, CEPI, and Gavi must work together.
In conclusion, the WHO, CEPI, and Gavi-led global virtual pooled inventory efforts aim to stockpile experimental vaccines for rare infectious diseases, with an emphasis on Marburg and Sudan Ebola. The strategy may speed up testing and response actions during outbreaks, and it could be used as a guide to combat other fatal diseases and improve worldwide pandemic preparedness.
